# A Narrative Review of Salivary Gland Extracellular Matrix and Sjögren’s Syndrome: Research Status and Future Prospects

## TL;DR

This review discusses how changes in the salivary gland extracellular matrix contribute to Sjögren’s Syndrome and explores potential new treatments.

## Contribution

The paper systematically reviews SG ECM changes in SS and explores novel therapeutic strategies targeting ECM regulation.

## Key findings

- ECM imbalance in salivary glands is central to Sjögren’s Syndrome pathogenesis.
- Dysregulated MMPs and fibrosis contribute to glandular destruction and loss of function.
- Current clinical treatments do not target ECM alterations, highlighting a need for new therapies.

## Abstract

Sjögren’s syndrome (SS) is a chronic systemic autoimmune disease characterized by the main clinical manifestation of oral and ocular dryness, predominantly affecting middle-aged and elderly women. As the most commonly affected target organs in SS, pathological changes in the salivary glands (SGs) and their underlying mechanisms are of great significance for understanding the disease progression. Recent studies have revealed that a dynamic imbalance of the extracellular matrix (ECM) in the SGs plays a crucial role in the pathogenesis of SS. Dysregulation of matrix metalloproteinases (MMPs) and the fibrotic processes they mediate constitute the core pathological changes. These alterations intertwine with local chronic inflammatory responses, cellular senescence, and hyperosmolarity, collectively leading to the destruction of the SG parenchymal structure and progressive loss of secretory function, significantly impairing the patients’ quality of life. However, research on the pathological mechanisms of the SG ECM remains insufficient, and there are currently no specific therapeutic interventions targeting ECM alterations in clinical practice. This review systematically elucidates the characteristics of pathological and physiological changes in the SG ECM in SS and thoroughly explores novel therapeutic strategies based on ECM regulation, as well as their clinical application prospects.